CLNN vs. APLM, BLRX, NRXP, AADI, BOLT, NXTC, CALC, RMTI, DARE, and PMN
Should you be buying Clene stock or one of its competitors? The main competitors of Clene include Apollomics (APLM), BioLineRx (BLRX), NRx Pharmaceuticals (NRXP), Aadi Bioscience (AADI), Bolt Biotherapeutics (BOLT), NextCure (NXTC), CalciMedica (CALC), Rockwell Medical (RMTI), Daré Bioscience (DARE), and ProMIS Neurosciences (PMN). These companies are all part of the "pharmaceutical preparations" industry.
Apollomics (NASDAQ:APLM) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.
In the previous week, Apollomics had 2 more articles in the media than Clene. MarketBeat recorded 4 mentions for Apollomics and 2 mentions for Clene. Apollomics' average media sentiment score of 1.43 beat Clene's score of 0.70 indicating that Clene is being referred to more favorably in the news media.
Apollomics has a net margin of 0.00% compared to Apollomics' net margin of -7,569.42%. Clene's return on equity of 0.00% beat Apollomics' return on equity.
Apollomics currently has a consensus target price of $5.00, suggesting a potential upside of 792.86%. Clene has a consensus target price of $6.50, suggesting a potential upside of 1,861.38%. Given Apollomics' higher probable upside, analysts plainly believe Clene is more favorable than Apollomics.
Clene has lower revenue, but higher earnings than Apollomics.
19.1% of Apollomics shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 26.6% of Clene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Clene received 53 more outperform votes than Apollomics when rated by MarketBeat users. However, 75.00% of users gave Apollomics an outperform vote while only 74.67% of users gave Clene an outperform vote.
Apollomics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Clene has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.
Summary
Clene beats Apollomics on 8 of the 15 factors compared between the two stocks.
Get Clene News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
